Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study

BACKGROUND: Immunogenicity of tumor necrosis factor alpha inhibitors (TNFis) has been recognized as an important problem that may cause loss of efficacy and adverse events such as infusion reactions. TNFis are being increasingly used among patients with Behçet syndrome (BS) and scarce data exist on...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Esatoglu, Sinem Nihal, Akkoc-Mustafayev, Fatma Nihan, Ozguler, Yesim, Ozbakır, Fatma, Nohut, Okan K., Cevirgen, Dilsen, Hamuryudan, Vedat, Hatemi, Ibrahim, Celik, Aykut Ferhat, Yazici, Hasan, Hatemi, Gulen
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782473/
https://ncbi.nlm.nih.gov/pubmed/33414791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.618973
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars